▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1749 by analyst upside · 2026-06-27
AHCO
AdaptHealth Corp.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+36.1%
implied upside to consensus target
Current Price $10.29
Consensus Target $14.0
Bull Target $18.0
Bear Target $11.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
2
Sell
0
52-Week Low $8.51
52-Week High $13.43
YTD Return +6.4%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 8.8x
EPS (TTM) $-0.59
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3.3B
Profit Margin -2.4%
52-WEEK RANGE
52-Week Low $8.51
52-Week High $13.43
Current Price $10.29
Bear Target $11.0
Bull Target $18.0
● Now $10.29 ● Target $14.0
TRADING DATA
Avg Volume 1.4M
YTD Return +6.4%
Analyst Count 8
Consensus Buy
Upside to Target +36.1%
Last Updated 2026-06-27

ANALYST SUMMARY

AdaptHealth Corp. (AHCO) is currently trading at $10.29 with a Wall Street consensus price target of $14.0, implying potential upside of 36.1% over the next 12 months. 8 analysts currently cover AHCO, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $11.0.

AHCO operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 6.4% year-to-date and is currently trading near the lower end of its 52-week range of $8.51 – $13.43.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ARDT +27.5%
Ardent Health, Inc.
$1B · P/E 10.4x · Buy
PAHC +43.9%
Phibro Animal Health Corporation
$1B · P/E 13.7x · Hold
NUTX +41.5%
Nutex Health Inc.
$1B · P/E 12.2x · Buy
COLL +48.5%
Collegium Pharmaceutical, Inc.
$1B · P/E 17.8x · Buy
INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AHCO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital — Reiterated
Outperform → Outperform 2026-05-11 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-06 Building track record
UBS — Reiterated
Buy → Buy 2026-05-06 33% win rate (6 calls)
Truist Securities — Reiterated
Buy → Buy 2026-04-13 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-02-26 29% win rate (7 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-11-06 Building track record
Truist Securities — Reiterated
Buy → Buy 2025-05-12 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2025-05-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
17/30
Consensus clarity
16/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →